Skip to main content
. 2022 Dec 1;12:1016295. doi: 10.3389/fonc.2022.1016295

Figure 2.

Figure 2

EFS by (A) multifocal disease and (B) RCB in patients without pCR after neoadjuvant chemotherapy. Panel (A) presents EFS for patients not achieving pCR with and without multifocal disease (yes/no) and panel (B) presents EFS for patients with RCB II vs. RCB III.